المؤلفون: Limonte, Christine P., Gao, Xiaoyu, Bebu, Ionut, Seegmiller, Jesse C., Lorenzi, Gayle M., Perkins, Bruce A., Karger, Amy B., Arends, Valerie L., Paterson, Andrew, Molitch, Mark E., de Boer, Ian H.

المساهمون: NIDDK

المصدر: Kidney International Reports ; ISSN 2468-0249

مصطلحات موضوعية: Nephrology

الإتاحة: https://doi.org/10.1016/j.ekir.2023.11.030Test
https://api.elsevier.com/content/article/PII:S246802492401489X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S246802492401489X?httpAccept=text/plainTest

المؤلفون: Polak, Joseph F, Backlund, Jye‐Yu C, Budoff, Matt, Raskin, Philip, Bebu, Ionut, Lachin, John M, Group, DCCT EDIC Research

المصدر: Journal of the American Heart Association. 10(24)

مصطلحات موضوعية: Heart Disease, Diabetes, Prevention, Cardiovascular, Nutrition, Heart Disease - Coronary Heart Disease, Clinical Research, Atherosclerosis, Metabolic and endocrine, Adult, Carotid Artery, Common, Carotid Intima-Media Thickness, Cohort Studies, Coronary Artery Disease, Diabetes Mellitus, Type 1, Female, Humans, Male, Risk Factors, Ultrasonography, carotid intima-media thickness, coronary artery disease, type 1 diabetes, DCCT/EDIC Research Group, carotid intima‐media thickness, Cardiorespiratory Medicine and Haematology

الوصف: Background Carotid artery intima-media thickness (IMT) is associated with the risk of subsequent cardiovascular events in the general population. This association has not been established in type 1 diabetes. Methods and Results We studied if carotid IMT is associated with the risk of a first coronary artery disease event in participants with type 1 diabetes in the EDIC (Epidemiology of Diabetes Interventions and Complications) study, the long-term observational follow-up of the DCCT (Diabetes Control and Complications Trial). Between 1994 and 1996, common carotid artery and internal carotid artery IMT were measured with high-resolution ultrasound in 1309 study participants with a mean age of 35 years and diabetes duration of 13.8 years; 52% were men. Cox proportional hazards models evaluated the association of standardized common carotid artery IMT and internal carotid artery IMT with subsequent cardiovascular events over the next 17 years. Models were adjusted for age, sex, mean hemoglobin A1c levels, and traditional cardiovascular risk factors. Associations of common carotid artery IMT with subsequent CAD were significant after adjustment for imaging device, sex, and age (hazard ratio [HR], 1.23 per 0.09 mm [95% CI, [1.04-1.45]; P=0.0141), but did not remain significant after further adjustment for traditional risk factors and hemoglobin A1c (HR, 1.14 per 0.09 mm [95% CI, 0.97-1.33]; P=0.1206). No significant associations with subsequent coronary artery disease events were seen for internal carotid artery IMT. Conclusions In the DCCT/EDIC cohort with type 1 diabetes, common carotid artery IMT, but not internal carotid artery IMT, is weakly associated with subsequent coronary artery events, an association eliminated after adjusting for coexistent traditional cardiovascular risk factors. Registration URL: https://www.clinicaltrials.govTest; Unique identifiers: NCT00360815 and NCT00360893.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/9f03q3wzTest

المؤلفون: Jenkins, Alicia, Braffett, Barbara, Basu, Arpita, Bebu, Ionut, Dagogo-Jack, Samuel, Orchard, Trevor, Wallia, Amisha, Lopes-Virella, Maria, Garvey, W, Lachin, John, Lyons, Timothy

المصدر: Scientific Reports. 11(1)

مصطلحات موضوعية: Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Heart Disease Risk Factors, Humans, Male, Metabolic Syndrome, Middle Aged, Uric Acid

الوصف: In type 2 diabetes, hyperuricemia is associated with cardiovascular disease (CVD) and the metabolic syndrome (MetS), but associations in type 1 diabetes (T1D) have not been well-defined. This study examined the relationships between serum urate (SU) concentrations, clinical and biochemical factors, and subsequent cardiovascular events in a well-characterized cohort of adults with T1D. In 973 participants with T1D in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC), associations were defined between SU, measured once in blood collected 1997-2000, and (a) concurrent MetS and (b) incident any CVD and major adverse cardiovascular events (MACE) through 2013. SU was higher in men than women [mean (SD): 4.47 (0.99) vs. 3.39 (0.97) mg/dl, respectively, p

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/7806b8k2Test
https://escholarship.org/content/qt7806b8k2/qt7806b8k2.pdfTest

المؤلفون: Larkin, Mary E, Nathan, David M, Bebu, Ionut, Krause-Steinrauf, Heidi, Herman, William H, Higgins, John M, Tiktin, Margaret, Cohen, Robert M, Lund, Claire, Bergenstal, Richard M, Johnson, Mary L, Arends, Valerie, Crandall, Jill P, McKee, Melissa Diane, Brown-Friday, Janet, Xhori, Entila, Ballentine-Cargill, Keisha, Duran, Sally, Lukin, Jennifer, Beringher, Stephanie, de la torre, Susana Gonzalez, Phillips, Lawrence, Burgess, Elizabeth, Olson, Darin, Rhee, Mary, Wilson, Peter, Raines, Tasha Stephanie, Costello, Julie, Gullett, Chona, Maher-Albertelli, Maxine, Morehead, Folayan, Mungara, Radhika, Person, Saranjit, Savoye, Louise, Sibymon, Mabil, Tanukonda, Sridhar, White, Carol Ann, Holloway, Leah, Adams, Cynthia, Ross, April, Balasubramanyam, Ashok, Gonzalez, Erica, Wright, Charlyne, Hollander, Priscilla, Roe, Erin, Uy, Analyn, Burt, Polly, Estrada, Lorie, Chionh, Kris, Ismail-Beigi, Faramarz, Falck-Ytter, Corinna, Kassem, Laure Sayyed, Sood, Ajay, Cramer, Bethany, Iacoboni, Jacalyn, Kononets, Maria V, Kulow, Tanya, Newman, Cynthia, Stancil, Katherine A, Sanders, Cristina, Tucker, Lisa, Werner, Amanda, Krol, Adrienne, McPhee, Gloria, Patel, Christine, Colosimo, Linda, Goland, Robin, Pring, James, Kringas, Patricia, Tejada, Jessica, Hausheer, Camille, Schneier, Harvey, Gumpel, Kelly, Kirpitch, Amanda, Green, Jennifer B, AbouAssi, Hiba, Chatterjee, Ranee, Feinglos, Mark N, Jones, Jennifer English, Khan, Shubi A, Kimpel, Jeanne B, Zimmer, Ronna P, Furst, Mary, Satterwhite, Barbara M, Thacker, Connie R, Kreider, Kathryn Evans, Mather, Kieren J, Lteif, Amale, Hamilton, Tonya, Patel, Nick, Riera, Gabriela, Jackson, Marcia, Pirics, Vivian, Howard, Devin, Aguillar, Danielle, Hurt, Sloan, Bergenstal, Richard, Carlson, Anders, Martens, Thomas, Johnson, Mary

المصدر: Diabetes Technology & Therapeutics. 21(12)

مصطلحات موضوعية: Diabetes, Clinical Research, Metabolic and endocrine, Black or African American, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hispanic or Latino, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Research Design, White People, Type 2 diabetes, Glycated hemoglobin, Interracial differences, Continuous glucose monitoring, Average glucose, GRADE Research Group, Clinical Sciences, Medical Physiology, Endocrinology & Metabolism

الوصف: Background: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study has enrolled a racially and ethnically diverse population with type 2 diabetes, performed extensive phenotyping, and randomly assigned the participants to one of four second-line diabetes medications. The continuous glucose monitoring (CGM) substudy has been added to determine whether there are racial/ethnic differences in the relationship between average glucose (AG) and hemoglobin A1c (HbA1c). CGM will also be used to compare time in target range, glucose variability, and the frequency and duration of hypoglycemia across study groups. Methods: The observational CGM substudy will enroll up to 1800 of the 5047 GRADE study participants from the four treatment groups, including as many as 450 participants from each of 4 racial/ethnic minority groups to be compared: Hispanic White, non-Hispanic White, non-Hispanic African American, and non-Hispanic Other. CGM will be performed for 2 weeks in proximity to a GRADE annual visit, during which an oral glucose tolerance test will be performed and HbA1c and glycated albumin measured. Indicators of interindividual variation in red blood cell turnover, based on specialized erythrocyte measurements, will also be measured to explore the potential causes of interindividual HbA1c variations. Conclusions: The GRADE CGM substudy will provide new insights into whether differences exist in the relationship between HbA1c and AG among different racial/ethnic groups and whether glycemic profiles differ among frequently used diabetes medications and their potential clinical implications. Understanding such differences is important for clinical care and adjustment of diabetes medications in patients of different races or ethnicities.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/3dp1c85hTest

المؤلفون: Basu, Arpita, Bebu, Ionut, Jenkins, Alicia J, Stoner, Julie A, Zhang, Ying, Klein, Richard L, Lopes-Virella, Maria F, Garvey, W Timothy, Budoff, Matthew J, Alaupovic, Petar, Lyons, Timothy J, Group, the Diabetes Control Complications Trial Epidemiology of Diabetes Interventions Complications Research

المصدر: Journal of Lipid Research. 60(8)

مصطلحات موضوعية: Medical Biochemistry and Metabolomics, Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Biological Sciences, Cardiovascular, Atherosclerosis, Prevention, Heart Disease, Heart Disease - Coronary Heart Disease, Good Health and Well Being, Adult, Apolipoproteins, Cardiovascular Diseases, Diabetes Complications, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, apolipoprotein C3, major adverse cardiac event, type 1 diabetes, Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications Research Group, Biochemistry & Molecular Biology, Biochemistry and cell biology, Medical biochemistry and metabolomics

الوصف: APOB, APOC3, and APOE and apolipoprotein-defined lipoprotein subclasses (ADLSs; based on qualitative apolipoprotein complement) have been associated with dyslipidemia and CVD. Our main objective was to define associations of serum apolipoproteins and ADLSs with "any CVD" and "major atherosclerotic cardiovascular events" (MACEs) in a prospective study of T1D. Serum apolipoproteins and ADLSs (14 biomarkers in total) were measured in sera (obtained between 1997 and 2000) from a subset (n = 465) of the Epidemiology of Diabetes Interventions and Complications cohort. Prospective associations of "any CVD" (myocardial infarction, stroke, confirmed angina, silent myocardial infarction, revascularization, or congestive heart failure) and MACEs (fatal or nonfatal myocardial infarction or stroke), over 5,943 and 6,180 patient-years follow-up, respectively, were investigated using Cox proportional hazards models that were unadjusted and adjusted for risk factors. During 15 years of follow-up, 50 "any CVD" events and 24 MACEs occurred. Nominally significant positive univariate associations with "any CVD" were APOB, APOC3 and its subfractions [heparin precipitate, heparin-soluble (HS)], and ADLS-defined Lp-B. In adjusted analyses, APOC3-HS remained nominally significant. Nominally significant positive univariate associations with MACEs were APOC3 and its subfractions and Lp-B:C; those with total APOC3 and APOC3-HS persisted in adjusted analyses. However, these associations did not reach significance after adjusting for multiple testing. There were no significant associations of APOA1, APOA2, APOE, or other ADLSs with either "any CVD" or MACEs. These hypothesis-generating data suggest that total serum APOC3 and APOC3 in HDL are potentially important predictive biomarkers for any CVD and MACEs in adults with T1D.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/8046r195Test

المؤلفون: Budoff, Matthew, Backlund, Jye-Yu C, Bluemke, David A, Polak, Joseph, Bebu, Ionut, Schade, David, Strowig, Suzanne, Raskin, Philip, Lachin, John M, Group, DCCT EDIC Research

المصدر: JACC Cardiovascular Imaging. 12(7)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Heart Disease - Coronary Heart Disease, Diabetes, Prevention, Autoimmune Disease, Aging, Patient Safety, Heart Disease, Good Health and Well Being, Adolescent, Adult, Computed Tomography Angiography, Coronary Angiography, Coronary Artery Disease, Diabetes Mellitus, Type 1, Disease Progression, Female, Humans, Incidence, Male, Middle Aged, Multidetector Computed Tomography, Predictive Value of Tests, Prognosis, Risk Factors, Time Factors, Vascular Calcification, Young Adult, cardiovascular disease, coronary artery calcification, major adverse cardiovascular event, type 1 diabetes, DCCT/EDIC Research Group, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences

الوصف: OBJECTIVES:This study sought to determine the relationship between coronary artery calcium (CAC) scores and subsequent cardiovascular disease (CVD) events in DCCT (Diabetes Control and Complications Trial)/EDIC (Epidemiology of Diabetes Interventions and Complications) participants. BACKGROUND:The CAC score has been validated for improved risk stratification in general populations; however, this association has not been well studied in type 1 diabetes (T1DM). METHODS:Computed tomography (CT) to measure CAC was performed in 1,205 DCCT/EDIC participants at a mean of 42.8 years of age during EDIC years 7 to 9, after the end of DCCT. This study analyzed the association between CAC and time to the first subsequent CVD event or to the first major adverse cardiac event (MACE), a follow-up of 10 to 13 years. CAC was categorized as: 0, >0 to 100, >100 to 300, or >300 Agatston units. RESULTS:Of 1,156 participants at risk for subsequent CVD, 105 had an initial CVD event (8.5 per 1,000 patient-years); and of 1,187 participants at risk for MACE, 51 had an initial MACE event (3.9 per 1,000 patient-years). Event rates among those with scores of zero (n = 817 [70.7%]) were very low for CVD (5.6 per 1,000 patient years). CAC scores >100 to 300 (hazard ratio [HR]: 4.17, 5.40) and >300 (HR: 6.06, 6.91) were associated with higher risks of CVD and MACE, respectively, compared to CAC of 0 (p < 0.0001). CAC scores >0 to 100 were nominally associated with CVD (HR: 1.71; p = 0.0415) but not with MACE (HR: 1.11; p = 0.8134). Similar results were observed when also adjusted for mean HbA1c and conventional CVD risk factors. The increment in the AUC due to CAC was modest. CONCLUSIONS:CAC scores >100 Agatston units were significantly associated with an increased risk of the subsequent occurrence of CVD and MACE in DCCT/EDIC cohort. (Diabetes Control and Complications Trial [DCCT]; NCT00360815; Epidemiology of Diabetes Interventions and Complications [EDIC]; NCT00360893).

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/2dq119c8Test

المؤلفون: Taylor, Peter N., Collins, Kimberly S., Lam, Anna, Karpen, Stephen R., Greeno, Brianna, Walker, Frank, Lozano, Alejandro, Atabakhsh, Elnaz, Ahmed, Simi T, Marinac, Marjana, Latres, Esther, Senior, Peter A., Rigby, Mark, Gottlieb, Peter A., Dayan, Colin M., Greenbaum, Carla, Krisher, Jeffrey, Skyler, Jay, Wherrett, Diane, Hannelius, Ulf, Lindqvist, Anton, Nowak, Christoph, Bebu, Ionut, Braffett, Barbara, Napolitano, Antonella, Jan Mohamed, Salim, Weir, Gordon, Nepom, Gerald, Beck, Roy, Richard, Claudia, Hedrick, Joseph, Ludvigsson, Johnny, Von Herrath, Matthias, Leon, Francisco, Ramos, Eleanor, Narendran, Parth, Gitelman, Stephen, Dabelea, Dana, Andrews, Rob, Haller, Michael, Jensen, Elizabeth, Harold, Kevan, Dutz, Jan

الوصف: BackgroundMetabolic outcomes in type 1 diabetes remain suboptimal. Disease modifying therapy to prevent β-cell loss presents an alternative treatment framework but the effect on metabolic outcomes is unclear. We, therefore, aimed to define the relationship between insulin C-peptide as a marker of β-cell function and metabolic outcomes in new-onset type 1 diabetes.Methods21 trials of disease-modifying interventions within 100 days of type 1 diabetes diagnosis comprising 1315 adults (ie, those 18 years and older) and 1396 children (ie, those younger than 18 years) were combined. Endpoints assessed were stimulated area under the curve C-peptide, HbA1c, insulin use, hypoglycaemic events, and composite scores (such as insulin dose adjusted A1c, total daily insulin, U/kg per day, and BETA-2 score). Positive studies were defined as those meeting their primary endpoint. Differences in outcomes between active and control groups were assessed using the Wilcoxon rank test.Findings6 months after treatment, a 24·8% greater C-peptide preservation in positive studies was associated with a 0·55% lower HbA1c (p<0·0001), with differences being detectable as early as 3 months. Cross-sectional analysis, combining positive and negative studies, was consistent with this proportionality: a 55% improvement in C-peptide preservation was associated with 0·64% lower HbA1c (p<0·0001). Higher initial C-peptide levels and greater preservation were associated with greater improvement in HbA1c. For HbA1c, IDAAC, and BETA-2 score, sample size predictions indicated that 2–3 times as many participants per group would be required to show a difference at 6 months as compared with C-peptide. Detecting a reduction in hypoglycaemia was affected by reporting methods.InterpretationInterventions that preserve β-cell function are effective at improving metabolic outcomes in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We have shown that improvements in HbA1c are directly proportional to the degree of C-peptide ...

وصف الملف: application/pdf

العلاقة: https://orca.cardiff.ac.uk/id/eprint/164272/1/PIIS221385872300267X.pdfTest; Taylor, Peter N. https://orca.cardiff.ac.uk/view/cardiffauthors/A337251L.htmlTest orcid:0000-0002-3436-422X orcid:0000-0002-3436-422X, Collins, Kimberly S., Lam, Anna, Karpen, Stephen R., Greeno, Brianna, Walker, Frank, Lozano, Alejandro, Atabakhsh, Elnaz, Ahmed, Simi T, Marinac, Marjana, Latres, Esther, Senior, Peter A., Rigby, Mark, Gottlieb, Peter A., Dayan, Colin M. https://orca.cardiff.ac.uk/view/cardiffauthors/A192115G.htmlTest orcid:0000-0002-6557-3462 orcid:0000-0002-6557-3462, Greenbaum, Carla, Krisher, Jeffrey, Skyler, Jay, Wherrett, Diane, Hannelius, Ulf, Lindqvist, Anton, Nowak, Christoph, Bebu, Ionut, Braffett, Barbara, Napolitano, Antonella, Jan Mohamed, Salim, Weir, Gordon, Nepom, Gerald, Beck, Roy, Richard, Claudia, Hedrick, Joseph, Ludvigsson, Johnny, Von Herrath, Matthias, Leon, Francisco, Ramos, Eleanor, Narendran, Parth, Gitelman, Stephen, Dabelea, Dana, Andrews, Rob, Haller, Michael, Jensen, Elizabeth, Harold, Kevan and Dutz, Jan 2023. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. The Lancet Diabetes & Endocrinology 11 (12) , pp. 915-925. 10.1016/S2213-8587(23)00267-X https://doi.org/10.1016/S2213-8587%2823%2900267-XTest file https://orca.cardiff.ac.uk/id/eprint/164272/1/PIIS221385872300267X.pdfTest

الإتاحة: https://doi.org/10.1016/S2213-8587Test(23)00267-X
https://orca.cardiff.ac.uk/id/eprint/164272Test/
https://orca.cardiff.ac.uk/id/eprint/164272/1/PIIS221385872300267X.pdfTest

المؤلفون: Crespo-Ramos, Gladys, Bebu, Ionut, Krause-Steinrauf, Heidi, Hoogendoorn, Claire J., Fang, Ran, Ehrmann, Dominic, Presley, Caroline, Naik, Aanand D., Katona, Aimee, Walker, Elizabeth A., Cherrington, Andrea, Gonzalez, Jeffrey S.

المساهمون: National Institutes of Health, Juvenile Diabetes Research Foundation United States of America, CDC, American Diabetes Association, NHLBI, National Institute of Diabetes and Digestive and Kidney Diseases

المصدر: Diabetes Research and Clinical Practice ; volume 203, page 110808 ; ISSN 0168-8227

مصطلحات موضوعية: Endocrinology, General Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine

الإتاحة: https://doi.org/10.1016/j.diabres.2023.110808Test
https://api.elsevier.com/content/article/PII:S0168822723005715?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0168822723005715?httpAccept=text/plainTest

المؤلفون: Karger, Amy B, Nasrallah, Ilya M, Braffett, Barbara H, Luchsinger, José A, Ryan, Christopher M, Bebu, Ionut, Arends, Valerie, Habes, Mohamad, Gubitosi-Klug, Rose A, Chaytor, Naomi, Biessels, Geert J, Jacobson, Alan M

المصدر: Diabetes Care ; ISSN:1935-5548

الوصف: To evaluate associations between plasma biomarkers of brain injury and MRI and cognitive measures in participants with type 1 diabetes (T1D) from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.

العلاقة: https://doi.org/10.2337/dc24-0229Test; https://pubmed.ncbi.nlm.nih.gov/38861647Test

الإتاحة: https://doi.org/10.2337/dc24-0229Test
https://pubmed.ncbi.nlm.nih.gov/38861647Test

المؤلفون: Gonzalez, Jeffrey S.^1,2,3,4 (AUTHOR) grademail@bsc.gwu.edu, Bebu, Ionut⁵ (AUTHOR), Krause-Steinrauf, Heidi⁵ (AUTHOR), Hoogendoorn, Claire J.^1,2 (AUTHOR), Crespo-Ramos, Gladys^1,2 (AUTHOR), Presley, Caroline⁶ (AUTHOR), Naik, Aanand D.⁷ (AUTHOR), Kuo, Shihchen⁸ (AUTHOR), Johnson, Mary L.⁹ (AUTHOR), Wexler, Deborah¹⁰ (AUTHOR), Crandall, Jill P.² (AUTHOR), Bantle, Anne E.¹¹ (AUTHOR), Arends, Valerie¹² (AUTHOR), Cherrington, Andrea L.¹³ (AUTHOR), Crandall, J.P. (AUTHOR), McKee, M.D. (AUTHOR), Behringer-Massera, S. (AUTHOR), Brown-Friday, J. (AUTHOR), Xhori, E. (AUTHOR), Ballentine-Cargill, K. (AUTHOR)

المصدر: Diabetes Care. Apr2024, Vol. 47 Issue 4, p610-619. 10p.

مصطلحات موضوعية: *TYPE 2 diabetes, *MENTAL depression, *GLUCAGON-like peptide-1 receptor, *COMPARATIVE method, *GLUCAGON-like peptide-1 agonists

مستخلص: OBJECTIVE: We evaluated whether adding basal insulin to metformin in adults with early type 2 diabetes mellitus (T2DM) would increase emotional distress relative to other treatments. RESEARCH DESIGN AND METHODS: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) of adults with T2DM of <10 years' duration, HbA1c 6.8–8.5%, and taking metformin monotherapy randomly assigned participants to add insulin glargine U-100, sulfonylurea glimepiride, the glucagon-like peptide-1 receptor agonist liraglutide, or the dipeptidyl peptidase 4 inhibitor sitagliptin. The Emotional Distress Substudy enrolled 1,739 GRADE participants (mean [SD] age 58.0 [10.2] years, 32% female, 56% non-Hispanic White, 18% non-Hispanic Black, 17% Hispanic) and assessed diabetes distress and depressive symptoms every 6 months. Analyses examined differences at 1 year and over the 3-year follow-up. RESULTS: Across treatments, diabetes distress (−0.24, P < 0.0001) and depressive symptoms (−0.67, P < 0.0001) decreased over 1 year. Diabetes distress was lower at 1 year for the glargine group than for the other groups combined (−0.10, P = 0.002). Diabetes distress was also lower for liraglutide than for glimepiride or sitagliptin (−0.10, P = 0.008). Over the 3-year follow-up, there were no significant group differences in total diabetes distress; interpersonal diabetes distress remained lower for those assigned to liraglutide. No significant differences were observed for depressive symptoms. CONCLUSIONS: Contrary to expectations, this randomized trial found no evidence for a deleterious effect of basal insulin on emotional distress. Glargine lowered diabetes distress modestly at 1 year rather than increasing it. Liraglutide also reduced diabetes distress at 1 year. Results can inform treatment decisions for adults with early T2DM. [ABSTRACT FROM AUTHOR]